Is Artiva Biotherapeutics, Inc. (ARTV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.2% / 30% | 131.6% / 30% | 0.1% / 30% | 2131.08% / 5% | ✗ NOT HALAL |
| DJIM | 10.2% / 33% | 131.6% / 33% | 0.1% / 33% | 2131.08% / 5% | ✗ NOT HALAL |
| MSCI | 6.8% / 33% | 88.5% / 33% | 0.1% / 33% | 2131.08% / 5% | ✗ NOT HALAL |
| S&P | 10.2% / 33% | 131.6% / 33% | 0.1% / 33% | 2131.08% / 5% | ✗ NOT HALAL |
| FTSE | 6.8% / 33% | 88.5% / 33% | 0.1% / 50% | 2131.08% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -56.5% | |
| Return on Assets (ROA) | -33.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$77M |
| Free Cash Flow | -$79M |
| Total Debt | $11M |
| Debt-to-Equity | 9.9 |
| Current Ratio | 8.6 |
| Total Assets | $131M |
Price & Trading
| Last Close | $5.16 |
| 50-Day MA | $4.97 |
| 200-Day MA | $3.63 |
| Avg Volume | 188K |
|
52-Week Range
$1.47
| |
About Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Artiva Biotherapeutics, Inc. (ARTV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Artiva Biotherapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Artiva Biotherapeutics, Inc.'s debt ratio?
Artiva Biotherapeutics, Inc.'s debt ratio is 10.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.8%.
What are Artiva Biotherapeutics, Inc.'s key financial metrics?
Artiva Biotherapeutics, Inc. has a market capitalization of $124M. Return on equity stands at -56.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.